EUVIMEDEUVIMED entdecken
Crossref

Engineered Cellular Vesicles Displaying Glycosylated Nanobodies for Cancer Immunotherapy

Jicheng Wu, Hailin Lu, Ximing Xu, Lang Rao iD, Yun Ge iD

Angewandte Chemie International Edition · 24.10.2024 · 63 (44)

DOI: 10.1002/anie.202404889 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 20.09.2024. Verfasst von Jicheng Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, 518132, China. Hauptthemen laut MEDLINE: Immunotherapy, Single-Domain Antibodies. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shenzhen Medical Research Fund, Shenzhen Bay Laboratory.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade targeting the CD47/SIRPα axis represents an alluring avenue for cancer immunotherapy. However, the compromised efficacy and safety concerns in vivo of conventional anti‐CD47 antibodies impede their wide clinical applications. Here we introduced a single type of high‐mannose glycans into the nanobody against CD47 (HM‐nCD47) and subsequently displayed HM‐nCD47 on cellular vesicles (CVs) for enhanced cancer immunotherapy. In this platform, the CVs significantly improved the circulation time of HM‐nCD47‐CVs, the nCD47 enabled the blockade of the CD47/SIRPα axis, and the HM enhanced recognition of mannose‐binding lectin, all synergistically activating the macrophage‐mediated antitumor immunity. In both subcutaneous and metastatic murine tumor models, the HM‐nCD47‐CVs possessed significantly extended half‐lives and increased accumulation at the tumor site, resulting in a remarkable macrophage‐dependent inhibition of tumor growth, a transcriptomic remodeling of the immune response, and an increase in survival time. By integrating the chemical biology toolbox with cell membrane nanotechnology, the HM‐nCD47‐CVs represent a new immunotherapeutic platform for cancer and other diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapySingle-Domain AntibodiesAnimalsMiceHumansGlycosylationNeoplasmsCD47 Antigen

Stichwörter der Autor:innen

Cancer ImmunotherapyGlycosylationNanobodyVesicles

Substanzen

Single-Domain AntibodiesCD47 Antigen

Autor:innen und Institutionen

  • Institute of Biomedical Health Technology and Engineering, Shenzhen Bay Laboratory, Shenzhen, 518132, China.
  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
  • Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen, 518132, China.
  • State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.

ORCID-Profile: Lang Rao, Yun Ge

Förderung

  • National Natural Science Foundation of China
  • Shenzhen Medical Research Fund
  • Shenzhen Bay Laboratory
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Wu, J., Lu, H., Xu, X., Rao, L., & Ge, Y. (2024). Engineered Cellular Vesicles Displaying Glycosylated Nanobodies for Cancer Immunotherapy. Angewandte Chemie International Edition, 63(44). https://doi.org/10.1002/anie.202404889

Vancouver

Wu J, Lu H, Xu X, Rao L, Ge Y. Engineered Cellular Vesicles Displaying Glycosylated Nanobodies for Cancer Immunotherapy. Angewandte Chemie International Edition. 2024;63(44). doi:10.1002/anie.202404889

BibTeX
@article{Wu2024,
  author = {Wu, Jicheng and Lu, Hailin and Xu, Ximing and Rao, Lang and Ge, Yun},
  title = {Engineered Cellular Vesicles Displaying Glycosylated Nanobodies for Cancer Immunotherapy},
  journal = {Angewandte Chemie International Edition},
  year = {2024},
  volume = {63},
  number = {44},
  doi = {10.1002/anie.202404889}
}
Kostenlos starten →